These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 16722036)

  • 1. Icodextrin preserves residual renal function in patients treated with automated peritoneal dialysis.
    Adachi Y; Nakagawa Y; Nishio A
    Perit Dial Int; 2006; 26(3):405-7. PubMed ID: 16722036
    [No Abstract]   [Full Text] [Related]  

  • 2. Use of icodextrin during nocturnal automated peritoneal dialysis allows sustained ultrafiltration while reducing the peritoneal glucose load: a randomized crossover study.
    Rodríguez-Carmona A; Pérez Fontán M; García López E; García Falcón T; Díaz Cambre H
    Perit Dial Int; 2007; 27(3):260-6. PubMed ID: 17468473
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sodium removal in patients undergoing CAPD and automated peritoneal dialysis.
    Rodríguez-Carmona A; Fontán MP
    Perit Dial Int; 2002; 22(6):705-13. PubMed ID: 12556073
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Icodextrin with small and short dwell enhances ultrafiltration in peritoneal dialysis patients with severe overhydration.
    Kuriyama S; Otsuka Y; Iida R; Matsumoto K; Hosoya T
    Perit Dial Int; 2006; 26(4):508-9. PubMed ID: 16881350
    [No Abstract]   [Full Text] [Related]  

  • 5. A novel "bimodal" use of icodextrin peritoneal dialysis solutions.
    Burkart J
    Kidney Int; 1998 Apr; 53(4):1089-90. PubMed ID: 9551423
    [No Abstract]   [Full Text] [Related]  

  • 6. Effect of Icodextrin Solution on the Preservation of Residual Renal Function in Peritoneal Dialysis Patients: A Randomized Controlled Study.
    Chang TI; Ryu DR; Yoo TH; Kim HJ; Kang EW; Kim H; Chang JH; Kim DK; Moon SJ; Yoon SY; Han SH;
    Medicine (Baltimore); 2016 Mar; 95(13):e2991. PubMed ID: 27043667
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Review of clinical trial experience with icodextrin.
    Wolfson M; Ogrinc F; Mujais S
    Kidney Int Suppl; 2002 Oct; (81):S46-52. PubMed ID: 12230481
    [No Abstract]   [Full Text] [Related]  

  • 8. Determination of alpha-amylase activity in serum and dialysate from patients using icodextrin-based peritoneal dialysis fluid.
    Anderstam B; García-López E; Heimbürger O; Lindholm B
    Perit Dial Int; 2003; 23(2):146-50. PubMed ID: 12713081
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evidence-based medicine in peritoneal dialysis: peritoneal dialysis solutions.
    Feriani M
    Contrib Nephrol; 2003; (140):202-8. PubMed ID: 12800361
    [No Abstract]   [Full Text] [Related]  

  • 10. Practical considerations when prescribing icodextrin: a narrative review.
    Silver SA; Harel Z; Perl J
    Am J Nephrol; 2014; 39(6):515-27. PubMed ID: 24925229
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Icodextrin does not impact infectious and culture-negative peritonitis rates in peritoneal dialysis patients: a 2-year multicentre, comparative, prospective cohort study.
    Vychytil A; Remón C; Michel C; Williams P; Rodríguez-Carmona A; Marrón B; Vonesh E; van der Heyden S; Divino Filho JC;
    Nephrol Dial Transplant; 2008 Nov; 23(11):3711-9. PubMed ID: 18556747
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The increase in plasma levels of Nepsilon-(carboxymethyl)lysine during icodextrin treatment of peritoneal dialysis patients is not associated with increased plasma levels of vascular cell adhesion molecule-1.
    Kooman JP; Schalkwijk CG; Konings CJ
    Perit Dial Int; 2006; 26(3):410-1. PubMed ID: 16722038
    [No Abstract]   [Full Text] [Related]  

  • 13. Beneficial effect of icodextrin on the hypertriglyceridemia of CAPD patients.
    Sisca S; Maggiore U
    Perit Dial Int; 2002; 22(6):727-9. PubMed ID: 12556078
    [No Abstract]   [Full Text] [Related]  

  • 14. Sodium removal and peritoneal dialysis modalities: no differences with optimal prescription of icodextrin.
    Fourtounas C; Dousdampanis P; Hardalias A; Vlachojannis JG
    Artif Organs; 2013 Jul; 37(7):E107-13. PubMed ID: 23461737
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Icodextrin: a review of its use in peritoneal dialysis.
    Frampton JE; Plosker GL
    Drugs; 2003; 63(19):2079-105. PubMed ID: 12962523
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Clinical experience with icodextrin. Multicenter study].
    Guerrero A; Montes R; Martín-Herrera C; Ruiz A; Remón C; Fernández-Ruiz EJ; Pérez-Bañasco V; Benítez M; Martínez-Benavides E; Martínez-González JM; Torán D; Tejuca F; Páez C; del Pino MD
    Nefrologia; 2001; 21(6):574-80. PubMed ID: 11881427
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Future of icodextrin as an osmotic agent in peritoneal dialysis.
    Pecoits-Filho R; Mujais S; Lindholm B
    Kidney Int Suppl; 2002 Oct; (81):S80-7. PubMed ID: 12230485
    [No Abstract]   [Full Text] [Related]  

  • 18. An update on peritoneal dialysis solutions.
    García-López E; Lindholm B; Davies S
    Nat Rev Nephrol; 2012 Feb; 8(4):224-33. PubMed ID: 22349485
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Icodextrin: an alternative peritoneal dialysis fluid.
    Chhabra D; Nash K
    Expert Opin Drug Metab Toxicol; 2008 Nov; 4(11):1455-64. PubMed ID: 18950286
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Effect of using icodextrin as a starting therapy for peritoneal permeability].
    Fernández-Reyes MJ; Bajo MA; del Peso G; Olea T; Sánchez-Villanueva RL; González E; Heras M; Sánchez R; Selgas R
    Nefrologia; 2009; 29(2):130-5. PubMed ID: 19396318
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.